Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Diamedica Therapeutics Inc (DMAC)
NASDAQ:DMAC
RESEARCH TOOLSreports
Diamedica Therapeutics (DMAC) Stock Price & Analysis
461 Followers
DMAC Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.94 - $3.73
Previous Close$3.25
Volume7.66K
Average Volume (3M)59.25K
Market Cap
$138.91M
Enterprise Value$86.42M
Total Cash (Recent Filing)$52.90M
Total Debt (Recent Filing)$400.00K
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Aug 13, 2024EPS Estimate
-$0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding37,963,916
10 Day Avg. Volume28,967
30 Day Avg. Volume59,250
Standard Deviation0.28
R-Squared0.11
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)1.61
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-4.32
Forecast
1Y Price Target
$7.00Price Target Upside115.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Diamedica Therapeutics News
PremiumCompany Announcements
Diamedica Therapeutics Expands Trials to Address Preeclampsia
PremiumCompany Announcements
Diamedica Therapeutics Files SEC Report
PremiumCompany Announcements
Diamedica Therapeutics Files Key SEC ReportRisk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DMAC FAQ
What was Diamedica Therapeutics Inc’s price range in the past 12 months?
Diamedica Therapeutics Inc lowest stock price was $1.94 and its highest was $3.73 in the past 12 months.
What is Diamedica Therapeutics Inc’s market cap?
Currently, no data Available
When is Diamedica Therapeutics Inc’s upcoming earnings report date?
Diamedica Therapeutics Inc’s upcoming earnings report date is Aug 13, 2024 which is in 22 days.
How were Diamedica Therapeutics Inc’s earnings last quarter?
Diamedica Therapeutics Inc released its earnings results on May 08, 2024. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.157 by $0.017.
Is Diamedica Therapeutics Inc overvalued?
According to Wall Street analysts Diamedica Therapeutics Inc’s price is currently Undervalued.
Does Diamedica Therapeutics Inc pay dividends?
Diamedica Therapeutics Inc does not currently pay dividends.
What is Diamedica Therapeutics Inc’s EPS estimate?
Diamedica Therapeutics Inc’s EPS estimate is -$0.16.
How many shares outstanding does Diamedica Therapeutics Inc have?
Diamedica Therapeutics Inc has 42,742,332 shares outstanding.
What happened to Diamedica Therapeutics Inc’s price movement after its last earnings report?
Diamedica Therapeutics Inc reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.157. Following the earnings report the stock price went down -6.34%.
Which hedge fund is a major shareholder of Diamedica Therapeutics Inc?
Currently, no hedge funds are holding shares in DMAC
---
Diamedica Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (115.38% Upside)
$7.00 (115.38% Upside)
Insider Transactions
Bought Shares
Worth $6.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.33%
12-Months-Change
Fundamentals
Return on Equity
-52.50%
Trailing 12-Months
Asset Growth
63.02%
Trailing 12-Months
Company Description
Diamedica Therapeutics Inc
DiaMedica Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It offers DM199 product which focuses on acute ischemic stroke (AIS), and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.
---
DMAC Earnings Call
Q1 2024
0:00 / 0:00
---
DMAC Stock 12 Month Forecast
Average Price Target
$7.00
▲(115.38% Upside)
Technical Analysis
Best Analysts Covering DMAC
1 Year
1 Year Success Rate
5/8 ratings generated profit
1 Year Average Return
+21.07%
reiterated a buy rating 26 days ago
Copying Thomas Flaten's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +21.07% per trade.
---